26Jul2018Betting on Biotech IPOs? What If You Buy the Third Rock and ARCH Portfolios?/Luke Timmerman/0/All, Venture Capital26 Jul 2018Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.